SSKN Stock Overview
A medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
STRATA Skin Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.03 |
| 52 Week High | US$6.96 |
| 52 Week Low | US$2.51 |
| Beta | 1.32 |
| 11 Month Change | -1.62% |
| 3 Month Change | 11.68% |
| 1 Year Change | -37.01% |
| 33 Year Change | -79.93% |
| 5 Year Change | -87.78% |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%
Aug 18
Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?
Aug 07STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business
Jun 07Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?
Mar 19STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 31Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?
Nov 03We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt
Jul 04STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company
Apr 18Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?
Jan 14STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M
Aug 10Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment
Jul 25What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 09Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years
Nov 24
Shareholder Returns
| SSKN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -9.5% | -0.8% | -1.2% |
| 1Y | -37.0% | 20.9% | 30.4% |
Return vs Industry: SSKN underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: SSKN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SSKN volatility | |
|---|---|
| SSKN Average Weekly Movement | 9.7% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SSKN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SSKN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 99 | Dolev Rafaeli | www.strataskinsciences.com |
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions.
STRATA Skin Sciences, Inc. Fundamentals Summary
| SSKN fundamental statistics | |
|---|---|
| Market cap | US$12.64m |
| Earnings (TTM) | -US$9.38m |
| Revenue (TTM) | US$32.68m |
0.4x
P/S Ratio-1.3x
P/E RatioIs SSKN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SSKN income statement (TTM) | |
|---|---|
| Revenue | US$32.68m |
| Cost of Revenue | US$14.55m |
| Gross Profit | US$18.13m |
| Other Expenses | US$27.51m |
| Earnings | -US$9.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.25 |
| Gross Margin | 55.47% |
| Net Profit Margin | -28.72% |
| Debt/Equity Ratio | 162.2% |
How did SSKN perform over the long term?
See historical performance and comparison